AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for MAVIRET™ – an oral therapy for the treatment of patients with hepatitis C

MAVIRET is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment*1 MAVIRET previously received a Notice of Compliance from Health Canada on August 16, 2017 MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease MONTREAL, Feb. 6, 2018 /CNW/ - AbbVie (NYSE: ABBV), a global, research and development-based ...

The Week in Review: October 20 – October 27, 2017

Friday, October 27, 2017 News Recap: Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6. We need to hear your voice by November 8, 2017!  AbbVie’s “GP” combo is pan-genotypic (works for all genotypes). Liver Meeting 2017: I’m A HCV Patient – Show Me What I Need to Know! Why reinvent the wheel? The good folks over at HCV New Drugs have put together this great overview o...

Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6

URGENT BC Patient and Caregiver Input Request: We need to hear your voice! Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6.  AbbVie’s “GP” combo is pan-genotypic (works for all genotypes).  Check out the background information in links below to learn the results that have been achieved in clinical trials to date. You will see that the cure rates across all genotypes are hig

AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017

- 16 HCV abstracts to be presented including 12 data presentations on the safety and efficacy of MAVYRET - MAVYRET is recommended in new AASLD guidelines as a first line treatment option for 8 weeks in treatment-naïve non-cirrhotic HCV patients across all genotypes (GT1-6) NORTH CHICAGO, Ill., Oct. 11, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development based biopharmaceutical company, today announced that it wi...

AbbVie’s 8-week hepatitis C drug granted early access in UK

A special Early Access to Medicines (EAMs) status has been granted in the UK to AbbVie’s as-yet-unapproved treatment for hepatitis C. The glecaprevir/pibrentasivr (g/p) combination is a ‘pan-genotypic’ drug  currently under review by the European Medicines Agency, and is part of a rapid evolution in treatments for the potentially deadly liver infection. AbbVie  is looking to compete with Gilead’s Epclusa, which was the first pan-genotypic hep C drug to

Two new hepatitis C therapies fast-tracked in Europe

Two drug combinations from Gilead and AbbVie that could improve treatment of chronic hepatitis C have been granted accelerated review in the EU. Gilead's application is for a three drug combination of NS5B polymerase inhibitor sofosbuvir, NS5A inhibitor velpatasvir and pan-genotypic protease inhibitor voxilaprevir – given over 12 weeks – that could achieve a cure for chronic hepatitis C virus (HCV) patients who have failed other regimens. The new direc

AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C

If approved, G/P will provide an eight week once-daily, ribavirin-free treatment option for HCV patients without cirrhosis across all major genotypes AbbVie's investigational regimen was granted Breakthrough Therapy Designation by the FDA for genotype 1 patients not cured with prior direct-acting antivirals AbbVie is on track to submit a Marketing Authorization Application for G/P in the European Union in early 2017 NORTH CHICAGO, ...

AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease

- 98 percent of patients across all major HCV genotypes (GT1-6) with severe chronic kidney disease (CKD), including patients on dialysis, achieved SVR12 with 12 weeks of G/P in the primary intent-to-treat analysis, regardless of previous treatment status or presence of compensated cirrhosis - 100 percent of patients achieved SVR12 in a modified intent-to-treat analysis - G/P is an investigational, pan-genotypic, once-daily, ribavirin-free, fixed-dose com...

Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C

 97.5 percent of chronic HCV infected patients without cirrhosis and new to treatment across all major genotypes (GT1-6) achieved SVR12 with 8 weeks of G/P Across the 8-week arms of three registrational studies, no patients discontinued treatment due to adverse events G/P is an investigational, pan-genotypic, once-daily, ribavirin-free regimen for the treatment of chronic HCV NORTH CHICAGO, Ill., Nov. 11, 2016 /PRNewswire/ -- AbbVie (N...

U.S.: AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

 Breakthrough Therapy Designation granted based on Phase 2 clinical data for genotype 1 (GT1) patients who failed previous therapy with direct-acting antivirals (DAAs)  Currently in Phase 3 clinical trials, glecaprevir/pibrentasvir (G/P) is an investigational, pan-genotypic regimen being evaluated for the treatment of chronic hepatitis C virus (HCV) genotypes 1-6  Breakthrough Therapy Designation is granted to investigational treatments for seri...